on Eckert & Ziegler Strahlen- Und Medizintechnik AG (ETR:EUZ)
Eckert & Ziegler Chosen for Manufacturing Archeus’ ART-101 Radiopharmaceutical
Berlin-based Eckert & Ziegler has secured a Master Service Agreement with Archeus Technologies for the contract manufacture of ART-101, a next-generation radiopharmaceutical. This agreement is crucial for the forthcoming Phase 1 clinical trial of ART-101 in the US, with production set at Eckert & Ziegler’s GMP facility in Boston.
ART-101 targets the prostate-specific membrane antigen and is being developed for prostate cancer imaging and treatment. Preclinical results suggest it could surpass existing therapies in pharmacology and tolerability. Dr. Harald Hasselmann of Eckert & Ziegler emphasized the facility's suitability for this early-phase development.
The collaboration signifies a milestone in advancing radiopharmaceutical solutions, with Eckert & Ziegler extending its service range from isotope supply to manufacturing.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Eckert & Ziegler Strahlen- Und Medizintechnik AG news